Ocera Therapeutics fka OCRX

[bbking2003]

Monday, April 15 • 3:30 - 6:30 pm
Enabling Macrocyclic Compounds for Drug Discovery: Opportunities, Challenges and Strategies
Instructors: Mark L. Peterson, Ph.D., Vice President, IP & Operations, Tranzyme Pharma

Macrocyclic compounds fill an important chemical space between small molecules and biologics. This course will discuss the recent developments in the field of macrocycle synthesis and screening, as well as specific aspects of these compounds for drug discovery and development purposes.

Unique characteristics of macrocycles
The challenges of macrocycle synthesis and screening
Current methods for synthesizing and screening macrocyclic compound libraries
Pros and cons of each methodology
Drug discovery and development considerations for macrocyclic molecules
Examples in the discovery of bioactive synthetic macrocycles
Remaining challenges and possible solutions
Dr. Peterson is currently Vice President, IP & Operations at Tranzyme Pharma. He was previously with Monsanto and Advanced ChemTech, where he worked in a wide variety of research areas including structure-based design, solid phase organic chemistry, combinatorial libraries, synthesis automation, heterocycles, unnatural amino acids, peptides and peptidomimetics. With Tranzyme Pharma since 1999, Dr. Peterson led the chemistry R & D efforts during the technology development stage of the company and the initiation of its drug discovery programs before assuming his present position in 2003. A native of Wisconsin, he received his Ph.D. in Organic Chemistry from Washington State University and conducted post-doctoral research at the University of Minnesota prior to starting his industrial career. He is author or co-author of over 80 publications and abstracted presentations plus two book chapters, as well as co-inventor on over 20 patents.http://www.drugdiscoverychemistry.com/dch_content.aspx?id=120704